Clinical Trial Update: Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rosuvastatin to prevent periprocedural myocardial necrosis during elective percutaneous coronary interventions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Periprocedural Myocardial Necrosis

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: University of Roma La Sapienza | Conditions: Periprocedural Myocardial Necrosis | Phase 3 | Status: COMPLETED